| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2013 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 35 | Q2 2024 | 10.5% |
| XENCOR ORD | 28 | Q2 2024 | 12.6% |
| PROTHENA ORD | 23 | Q2 2024 | 28.0% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| GALAPAGOS NV SPON ADR | 22 | Q2 2024 | 12.0% |
| MORPHIC HOLDING ORD | 21 | Q2 2024 | 8.5% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| ANAPTYSBIO INC | 19 | Q2 2024 | 8.3% |
| ARVINAS INC | 18 | Q2 2024 | 7.2% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | May 31, 2024 | 5,717,324 | 5.9% |
| Morphic Holding, Inc. | May 03, 2024 | 3,014,752 | 6.0% |
| LENZ Therapeutics, Inc. | April 08, 2024 | 1,219,774 | 4.8% |
| Adaptimmune Therapeutics PLC | March 26, 2024 | 164,424,420 | 10.7% |
| Crinetics Pharmaceuticals, Inc. | March 11, 2024 | 4,155,375 | 5.3% |
| Zymeworks Inc. | February 22, 2024 | 14,132,291 | 20.0% |
| iTeos Therapeutics, Inc. | February 16, 2024 | 1,944,672 | 5.4% |
| ABEONA THERAPEUTICS INC. | February 14, 2024 | 1,086,956 | 4.2% |
| Adicet Bio, Inc. | February 14, 2024 | ? | ? |
| Aligos Therapeutics, Inc. | February 14, 2024 | 7,264,147 | 10.0% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| SC 13G | 2024-09-03 |
| SC 13D | 2024-08-23 |
| 4 | 2024-08-16 |
| SC 13D/A | 2024-08-16 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-07-01 |
| SC 13G | 2024-05-31 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-03 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.